NMFA

NMFA

NMFA™ provides technology and services towards accelerating drug development using an integrative platform for quantitative modeling of complex molecular pathways for treatment of Alzheimer’s Disease using the revolutionary CytoSolve® platform. The CytoSolve platform uses in-silico modeling to bridge in-vitro testing with human clinical trials with the goal of eliminating animal experimentation. NMFA™ is built on the foundation of computational biology, a field that is in rapid transition from diagrammatic representation of pathways to quantitative and predictive mathematical models, which span time-scales, knowledge domains and spatial-scales. This transition is being accelerated by high-throughput experimentation which isolates reactions and their corresponding rate constants.